

FOR IMMEDIATE RELEASE

March 2002

David Karlman
Chairman and Chief Executive Officer
American BioHealth Group, LLC
15721 Bernardo Heights Parkway Suite 151
San Diego, California 92128
(ph) 858-675-3600
(fax) 858-613-0748
dkarlman@abgpharma.com

**American BioHealth Group Advancing Navy Medical Breakthrough Promising
Hearing Loss Restoration and Protection to Millions**

SAN DIEGO, Calif.--American BioHealth Group, LLC has signed an exclusive license with the United States Navy for a new and novel pharmaceutical technology developed by the Naval Medical Center-San Diego for the prevention and treatment of acute hearing loss resulting from noise and chemical exposure.

The technology, a family of unique antioxidant compounds, has been shown to effectively prevent and restore hearing loss in animal models exposed to various noise insults and cancer therapies. This was developed under the direction of Army Colonel Richard D. Kopke, MD, by researchers at Naval Medical Center-San Diego, and researchers at the State University of New York at Buffalo. This future pharmaceutical development promises to aid tens of millions of Americans at risk for sensorineural hearing loss.

"This is a seminal moment for the 39 million plus individuals that are at risk and suffer from hearing loss due to noise or chemical exposure," said David Karlman, Chairman and Chief Executive Officer of American BioHealth Group, LLC. "Dr. Kopke's team of talented researchers have committed years to the specific discipline of finding a cure for sensorineural hearing loss. This agreement further verifies the magnitude of their contribution and will result in needed pharmaceutical products to help tens of millions of Americans who today have no pharmaceutical treatment options for the prevention or restoration of sensorineural hearing loss. We are honored to be the organization chosen to work with the Naval Medical Research Center in San Diego, Dr. Kopke, and the Office of Naval Research to bring this exciting research to

Under the terms of the exclusive license agreement, American BioHealth Group will conduct clinical research, product development and have an exclusive license to market the products for the protection and restoration of hearing loss. The compounds that will be developed and commercialized by American BioHealth Group have already been approved by the FDA for other indications and have acceptable, well-proven safety profiles.

Mark Mugerditchian, President and Chief Operating Officer states, "For the first time, physicians will be able to treat individuals suffering from sensorineural hearing loss using a pharmaceutical product that has gone through the rigorous safety and efficacy testing required by FDA. We believe that our first product, once approved, will be the first pharmaceutical product in the marketplace targeted at these indications. Our goal is to develop a series of products based on this technology, that addresses this significant unmet medical need."